Duic Cameron, Pfau Kristina, Keenan Tiarnan D L, Wiley Henry, Thavikulwat Alisa, Chew Emily Y, Cukras Catherine
Unit on Clinical Investigation of Retinal Diseases, National Eye Institute, National Institute of Health, Bethesda, Maryland.
Unit on Clinical Investigation of Retinal Diseases, National Eye Institute, National Institute of Health, Bethesda, Maryland; Department of Ophthalmology, University Hospital Bonn, Bonn, Germany.
Ophthalmol Retina. 2023 Apr;7(4):307-317. doi: 10.1016/j.oret.2022.11.006. Epub 2022 Nov 17.
PURPOSE: To analyze presence of hyperreflective foci (HRF) across different age-related macular degeneration (AMD) severities and examine its correlation with other structural and functional AMD features. DESIGN: Longitudinal, single-center, case-control study. PARTICIPANTS: One hundred and fifty-eight participants aged > 50 years old with varying AMD severities (including no AMD). METHODS: Color fundus imaging was used to assess AMD severity and hyperpigmentation (PGM) presence. Subretinal drusenoid deposits (SDD) and HRF were detected on OCT volumes. The correlations of HRF with additional AMD features were evaluated using linear and logistic mixed-effects models. One study eye per participant underwent dark adaptation (DA) testing to measure rod intercept time (RIT) for structure function associations. Eyes were followed longitudinally and changes in AMD severity and RIT were measured relative to HRF presence. MAIN OUTCOME MEASURES: The primary outcome was presence of HRF, which was compared with presence of other AMD features and DA impairment. RESULTS: One hundred and fifty-eight participants (median baseline age of 73.1 [interquartile range (IQR) = 66-79] years) contributing 1277 eye visits were included. Hyperreflective foci (HRF) were detected more frequently in higher AMD severities. Hyperreflective-foci presence was significantly associated with PGM presence (odds ratio 832.9, P < 0.001) and SDD presence (odds ratio 9.42, P = 0.017). Eyes with HRF demonstrated significantly longer DA (median 27.1 [IQR = 16-40] minutes) than those without HRF (13.5 [10-22] minutes) but less than eyes with SDD only (40 [28-40] minutes). Highest RIT values were found in eyes with both HRF and SDD (40.0 [40-40] minutes). Age and HRF explained a similar proportion of RIT variability as age and SDD. Eyes that developed HRF demonstrated baseline RITs closer to eyes with HRF at baseline, compared with eyes that never developed HRF (29.1 [16-40], 38.5 [22-40] versus 13.1 [10-22] minutes; Kruskal-Wallis P < 0.001). CONCLUSIONS: The progressively increased presence of HRF in higher AMD severities, and its correlation with previously associated AMD biomarkers, suggests HRF is an important OCT feature adding to the understanding of disease progression. Hyperreflective foci presence was associated with delays in DA, indicating HRF is a marker for visual cycle impairment. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
目的:分析不同严重程度的年龄相关性黄斑变性(AMD)中高反射灶(HRF)的存在情况,并研究其与AMD其他结构和功能特征的相关性。 设计:纵向、单中心、病例对照研究。 参与者:158名年龄大于50岁、AMD严重程度各异(包括无AMD)的参与者。 方法:采用彩色眼底成像评估AMD严重程度和色素沉着过度(PGM)情况。在OCT容积上检测视网膜下类玻璃膜疣沉积物(SDD)和HRF。使用线性和逻辑混合效应模型评估HRF与其他AMD特征的相关性。每位参与者的一只研究眼接受暗适应(DA)测试,以测量视杆细胞截距时间(RIT),用于结构功能关联研究。对眼睛进行纵向随访,并测量相对于HRF存在情况的AMD严重程度和RIT变化。 主要观察指标:主要观察指标为HRF的存在情况,并与其他AMD特征的存在情况和DA损害进行比较。 结果:纳入158名参与者(基线年龄中位数为73.1岁[四分位间距(IQR)=66 - 79岁]),共进行了1277次眼科检查。在更高AMD严重程度中更频繁地检测到高反射灶(HRF)。HRF的存在与PGM的存在显著相关(优势比832.9,P<0.001)和SDD的存在显著相关(优势比9.42,P = 0.017)。有HRF的眼睛显示出比没有HRF的眼睛明显更长的DA(中位数27.1[IQR = 16 - 40]分钟),但比仅有无SDD的眼睛短(40[28 - 40]分钟)。在既有HRF又有SDD的眼睛中发现最高的RIT值(40.0[40 - 40]分钟)。年龄和HRF解释的RIT变异性比例与年龄和SDD相似。与从未出现HRF的眼睛相比,出现HRF的眼睛在基线时的RIT更接近基线时有HRF的眼睛(29.1[16 - 40]、38.5[22 - 40]与13.1[10 - 22]分钟;Kruskal - Wallis检验P<0.001)。 结论:在更高AMD严重程度中HRF的存在逐渐增加,以及其与先前相关的AMD生物标志物的相关性,表明HRF是一个重要的OCT特征,有助于加深对疾病进展的理解。HRF的存在与DA延迟相关,表明HRF是视觉循环损害的一个标志物。 财务披露:在参考文献之后可能会发现专有或商业披露信息。
Graefes Arch Clin Exp Ophthalmol. 2023-10
Invest Ophthalmol Vis Sci. 2018-5-1
Ophthalmol Retina. 2024-7
Eye (Lond). 2025-2
Mol Neurodegener. 2024-6-18
Graefes Arch Clin Exp Ophthalmol. 2024-11